Cargando…
Advancing clinical development pathways for new CFTR modulators in cystic fibrosis
Cystic fibrosis (CF) is a life-shortening genetic disease affecting approximately 70 000 individuals worldwide. Until recently, drug development efforts have emphasised therapies treating downstream signs and symptoms resulting from the underlying CF biological defect: reduced function of the CF tra...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4853537/ https://www.ncbi.nlm.nih.gov/pubmed/26903594 http://dx.doi.org/10.1136/thoraxjnl-2015-208123 |